Our research focus

Product pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT-595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT-595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Fibrinogen (BT-524) - Acquired Fibrinogen Deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis
Trimodulin (BT-086) - Severe community acquired pneumonia
(BT-063) - Systemic lupus erythematosus
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
Tregalizumab (BT-061) - other diseases

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information